New patent strengthens Alterity’s Parkinson’s investment

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

USPTO grant strengthens Alterity’s IP position and opens a path for ATH434 into Parkinson’s disease investment.

Patents rarely make headlines outside the biotech trade press, but for a clinical-stage company preparing to enter a pivotal trial, a strong patent estate can matter as much as the data itself.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2569

Alterity Therapeutics

Longevity level(s):

  • Level 5: Aging disease management
    Therapeutic interventions that manage the symptoms of diagnosed aging diseases (i.e. current mainstream healthcare) and biotechnology companies focused on developing drugs to treat age-related diseases.
  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

Alterity Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinsonian disorders including Multiple System Atrophy and Parkinson's disease. The company's lead candidate, ATH434, is an oral small molecule that inhibits alpha-synuclein aggregation by targeting excess iron accumulation in the central nervous system through an iron-chaperone mechanism. Alterity's therapeutic approach addresses fundamental pathological mechanisms underlying neurodegeneration, with the mission to improve clinical outcomes and quality of life for patients with progressive neurological disorders.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Old dogs, new funding: Dog Aging Project fetches $29m from NIH

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE